为了进一步证实AT对NAFLD的缓解机制，测定了AT对Hepg2细胞的

To further confirm the mitigation mechanism of AT on NAFLD, the effect of AT on Hepg2 cells was determined. First, the effect of AT on Hepg2 cell viability was assessed by cck-8 assay. We found that Hepg2 cells treated with AT concentrations below 300 μM showed no change in viability. However, AT treatment at a concentration of 400 μM or above reduced the viability of BV-2 cells. Therefore, we chose a dose of 200 μM to study the effect of AT on Hepg2 cells.

In order to further confirm the remission mechanism of at on NAFLD, the effect of at on HepG2 cells was measured. Firstly, the effect of at on the viability of HepG2 cells was evaluated by CCK-8 assay. We found that less than 300 μ HepG2 cells treated with at at concentration of M showed no change in viability. However, the concentration is 400 μ At treatment of M or more decreased the viability of BV-2 cells. So we chose 200 μ M to study the effect of at on HepG2 cells.

In order to further confirm the remission mechanism of AT on NAFLD, the effect of AT on Hepg2 cells was measured. Firstly, the effect of AT on the viability of Hepg2 cells was evaluated by cck-8 assay. We found that Hepg2 cells treated with AT concentration less than 300μM did not show any change in vitality. However, AT treatment with a concentration of 400 μM or more decreased the viability of BV-2 cells. Therefore, we chose a dose of 200μM to study the effect of AT on Hepg2 cells.